Which Hypoglycemic Drug Is Better for Diabetic Nephropathy
Diabetic Nephropathy is one of the most common complications of Diabetes mellitus. About 20% to 40% of Chinese diabetic patients suffer from diabetic nephropathy due to different degrees of renal damage.
Vascular variations caused by prolonged elevated blood sugar are difficult to recover, leading to greater risk of kidney damage. Generally, diabetics with a history of more than 10 years of diabetes are more likely to have kidney disease, while diabetes mellitus and kidney disease together are more destructive, which can speed up Kidney Failure.
Diabetics should try their best to avoid the occurrence of renal failure, and the key point is to control blood sugar. Adherence to taking hypoglycemic drugs is fundamental to the sustained stability of blood sugar. In addition to high blood sugar, diabetic nephropathy patients will also have high blood pressure, proteinuria and other symptoms. In order to maintain the stability of renal function, several or even more than a dozen drugs need to be taken. And to reduce the workload of kidneys, the best medication treatment is required.
Which hypoglycemic drug is the best choice for Diabetic Nephropathy? 2 drugs are preferred.
Metformin is the basic drug for the treatment of type 2 diabetes mellitus, and basically all diabetic patients should take it. But in recent years, many diabetics have such questions: can Metformin damage the kidneys? In fact, this is a misunderstanding. Metformins are not suitable for patients with renal insufficiency (serum creatinine exceeds 132.6 umol/l) and severe diabetic nephropathy. But it's not because metformin can damage the kidney.
Patients with renal insufficiency and severe renal failure can not better metabolize endotoxins. Long-term use of metformin has the risk of acidosis, while patients with severe renal insufficiency have a greater risk. Therefore, metformin drugs are not recommended. Metformin can be administered to patients with early stage of nephropathy and normal renal function.
Therefore, diabetic nephropathy patients should take the medicine according to the condition.
SGLT-2 inhibitor, sodium-glucose synergistic transporter 2 inhibitor, is a new type of hypoglycemic drug developed in recent years. It is different from other drugs mainly by inhibiting the absorption of glucose by the kidney and metabolizing more sugar from the urine to reduce blood levels, rather than by regulating insulin.
Several clinical studies have shown that these hypoglycemic drugs not only reduce blood sugar level, but also reduce blood pressure, weight control, reduce the risk of diabetic Cardiovascular Disease. More importantly, they have the effect of delaying renal failure. The drug can also be taken in combination with metformin and other hypoglycemic drugs.
At present, there are six SGLT-2 inhibitors on the market in the world, including cangliben, dagliben, engliben, eggliben, rugliben and togliben.
It is worth noting that diabetic nephropathy patients with severe renal impairment, including renal failure and uremia, are not recommended to use such drugs. Generally, it is better not to use when glomerular filtration rate is less than 45 mL/min.1.73 m2. For end-stage kidney disease, blood sugar level is not too high with regular Dialysis.
Which hypoglycemic drug is better for Diabetic Nephropathy? Now you get the answer. If you still have any other questions on Diabetic Nephropathy, please leave a message below or contact online doctor.
***Please seek professional medical advise for the diagnosis or treatment of any ailment, disease or medical condition. This article is not intended to be a substitute for the advice of a licensed medical professional.***